Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
China Issues White Paper on Community with Shared Future in CyberspaceCCTF Wins Another Full Score in FTI ReportXi Focus: Xi Stresses Striving in Unity to Fulfill Goals Set by Party CongressChina launches campaign to boost grain outputChina Focus: China Releases Measures to Optimize COVIDXi Jinping: CPC Is a Party of the People and for the PeopleXi Meets Pakistani PMXi Jinping: CPC Is a Party of the People and for the People(CPC Congress) CPC Elects New Central Committee, New Central Commission for Discipline InspectionChina's used vehicle sales up in first 2 months
2.4989s , 6500.7734375 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,Global Gleam news portal